GEN Exclusives

More »

GEN News Highlights

More »
Jul 12, 2011

Shimadzu UK Opens Evaluation Laboratory to Bolster Use of Customized Application Solutions

  • Shimadzu UK unveiled a 1,500 m² product evaluation laboratory at its central U.K. headquarters in Milton Keynes, Buckinghamshire. The center, which aims to focus on excellence in customized application solutions, has 25 analytical systems including the firm’s complete range of products and a wide selection of its array of LC, GC, LC/MS, GC/MS, and spectroscopy instrumentations.

    The facility is supported by a dedicated on-site team of eight lab instrumentation professionals. “We are striving to make our new Evaluation Laboratory a center for excellence where existing customers or potential new ones can be safe in the knowledge that they can try out various pieces of equipment and run them through their paces before deciding what is the best system solution to meet their particular application requirements,” explains Colin Jump, Shimadzu UK’s managing director. 

    “Our goal is best-in-class equipment as well as post-sales service and support. The new center will help us to support our customers and their Shimadzu equipment throughout its working life. Shimadzu offers scheduled training courses at competitive rates for both basic and advanced equipment and software use as well as applications courses designed by our experts to meet a user’s requirements."

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »